Tolerability and Safety Profile of a New Brand-Generic Product of Glatiramer Acetate in Iranian Patients with Relapsing-Remitting Multiple Sclerosis: An Observational Cohort Study

机译：醋酸格拉替雷新品牌通用产品在患有复发缓解型多发性硬化症的伊朗患者中的耐受性和安全性概况：一项观察性队列研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThe aim of this study was to evaluate the safety, tolerability, and efficacy of a brand-generic glatiramer acetate product in patients with relapsing-remitting multiple sclerosis over a 12-month period. A noninterventional cohort study was conducted on 185 patients. The patients had a confirmed and documented diagnosis of relapsing-remitting multiple sclerosis as defined by the Revised McDonald Criteria (2010), were ambulatory with a Kurtzke Expanded Disability Status Scale score of 0 to 5.5, and their treatment by glatiramer acetate 40 mg/mL was just started.

机译：背景本研究的目的是评估品牌通用醋酸格拉替雷在12个月内复发缓解型多发性硬化症患者中的安全性，耐受性和疗效。一项针对185名患者的非干预队列研究。根据修订的McDonald Criteria（2010）定义，患者已确诊并记录有复发缓解型多发性硬化症的诊断，正在非门诊治疗，Kurtzke扩展残疾状态量表评分为0到5.5，接受醋酸格拉替雷治疗40 mg / mL才刚刚开始。

著录项

期刊名称 Current Therapeutic Research Clinical and Experimental
作者
Roya Abolfazli; Shirin Pournourmohammadi; Ahmadreza Shamshiri; Sara Samadzadeh;
展开▼
作者单位

展开▼
年(卷),期 2018(88),-1
年度 2018
页码 47–51
总页数 5
原文格式 PDF
正文语种
中图分类药学;医学史;
关键词
adverse drug reaction efficacy glatiramer acetate multiple sclerosis safety tolerability;

机译：药物不良反应;疗效;醋酸格拉替雷;多发性硬化;安全性;耐受性;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study [J] . Khan Omar, Rieckmann Peter, Boyko Alexey, Multiple sclerosis: clinical and laboratory research . 2017,第6期

机译：三次每周给药方案的疗效和安全性醋酸三次醋酸多发性硬化症患者的疗效和安全性：Glatamer乙酸盐低频管理的3年结果开放标签扩展研究
2. Efficacy and Safety of a Three-times Weekly Dosing Regimen of Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis Patients: 3-Year Results of the Glatiramer Acetate Low-Frequency Administration (GALA) Open-Label Extension Study. [J] . Kolodny S., Khan O., Rieckmann P., Multiple sclerosis: clinical and laboratory research . 2016,第3期

机译：醋酸格拉替雷在复发-缓解型多发性硬化症患者中每周三次给药方案的疗效和安全性：醋酸格拉替雷低频管理（GALA）开放标签扩展研究的3年结果。
3. A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate. [J] . Debouverie M, Moreau T, Lebrun C, European journal of neurology: the official journal of the European Federation of Neurological Societies . 2007,第11期

机译：一项纵向观察性研究，研究对象是醋酸格拉替雷治疗的复发缓解型多发性硬化症患者。
4. A User Study About Designing a Mobile App for Motivating Multiple Sclerosis Patients for Self-rehabilitation [C] . Clemence Chassan, Celine Jost, Marc Sevene, International Conference on Computers Helping People with Special Needs . 2020

机译：关于设计移动应用的用户研究，用于激励多发性硬化患者自我康复
5. An investigation of early relapsing-remitting multiple sclerosis patients using diffusion tensor imaging and spectroscopy. [D] . Zaini, Wan Hazlin. 2013

机译：使用扩散张量成像和光谱法对早期复发缓解型多发性硬化症患者进行调查。
6. Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis [O] . Jonathan Calkwood, Timothy Vollmer, Robert J. Fox, 2016

机译：延缓释放富马酸二甲酯与干扰素β或醋酸格拉替雷在复发性多发性硬化症中的安全性和耐受性
7. Safety and tolerability data of a new brand-generic product of teriflunomide in iranian relapsing-remitting multiple sclerosis patients: An observational cohort study [O] . R. Abolfazli, A. Hekmat, M. Ghazaeian, 2019

机译：伊朗复发式多发性硬化症患者的伊利菲德新品牌仿制产品的安全性和可耐受性数据：观察队列研究

Tolerability and Safety Profile of a New Brand-Generic Product of Glatiramer Acetate in Iranian Patients with Relapsing-Remitting Multiple Sclerosis: An Observational Cohort Study

摘要

著录项

相似文献

相关主题

期刊订阅